Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s
Teva has added yet another critical failure for laquinimod, which may finally be put on the chopping block.
The company’s partners at Active Biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
